Biotech Daily

Tuesday July 21, 2026

Daily news on ASX-listed biotechnology companies

*** ASX FLAT, BIOTECH DOWN: LUMOS UP 24%; IMPEDIMED, MICRO-X DOWN 9%**

*** TELIX UNAUDITED H1 REVENUE UP 22% TO $681m**

*** CONTROL BIONICS SPP RAISES $256k, $244k SHORTFALL, TOTAL $9.75m**

*** TGA SUSPENDS TOUCH CHLAMYDIA, GONORRHOEA SELF-TESTS**

*** MESOBLAST M-D PROF ITESCU $2.7m OPTIONS EXERCISE**

*** TELIX TREATS 1st PHASE III TLX250-Tx RENAL CANCER PATIENT**

*** OPTISCAN BEGINS STAGE 2 HEAD, NECK IMAGING STUDY**

*** RHYTHM DEVELOPS GENETYPE LUNG CANCER RISK TEST**

*** BLS, CAYMAN CHEMICAL PSYCHEDELICS COMMERCIALIZATION**

*** PYC: 'PYC-001 INCREASES RETINAL GENE EXPRESSION, IN MONKEYS'**

*** IDT FORECASTS REVENUE UP 2.5% TO $20m; LOSS DOWN 85% TO $950k**

*** CLINUVEL ADSs FALL 3% ON LEVEL II NASDAQ TRADING**

MARKET REPORT

The Australian stock market edged up 0.02 percent on Tuesday July 21, 2026, with the ASX200 up 2.0 points to 8,793.3 points. Thirteen of the Biotech Daily Top 40 companies were up, 22 fell, four traded unchanged and one was untraded. All four Big Caps fell.

Lumos was the best, on a Febridx US commercialization update, up 1.9 cents or 23.75 percent to 9.9 cents, with 18.7 million shares traded. Atomo climbed 18.75 percent; Nova Eye was up 17.4. percent; Compumedics rose 13.95 percent; Curvebeam climbed 5.9 percent; Imricor rose 4.2 percent; Avita was up 3.9 percent; Dimerix, Imugene, Prescient and Racura rose two percent or more; with Artrya and Telix up by less than one percent.

Impedimed and Micro-X led the falls, both down 9.1 percent to 0.5 cents and 3.0 cents, respectively, with 105,586 shares and 2.3 million shares traded, respectively. Botanix lost 7.7 percent; both Aroa and Optiscan were down 6.7 percent; EBR fell 5.7 percent; Mesoblast lost 4.5 percent; Clarity, Pro Medicus and Proteomics were down three percent or more; Actinogen, Alcidion, Emvision, Immutep and Polynovo shed two percent or more; Clinuvel, CSL, Medical Developments, Nanosonics, Neuren, Saluda and Starpharma were down one percent or more; with 4D Medical, Cochlear, Orthocell and Resmed down by less than one percent.

TELIX PHARMACEUTICALS

Telix says unaudited revenue for the six months to June 30, 2026 were up 22.2 percent to $US477 million ($A681 million), compared to the previous corresponding period.
Last year, Telix said revenue for the six months to June 30, 2025 rose 62.9 percent to $US390,359,000, with net profit after tax down 87.3 percent to $US3,255,000 (BD: Aug 21, 2025).
Today, the company said revenue for the three months to June 30, 2026 was up 22.9 percent to $US247 million, with revenue from its Illuccix and Gozellix prostate specific membrane antigen (PSMA) radio-pharmaceutical prostate cancer imaging kits up 30.3 percent to $US155 million and third-party revenue, predominantly from RLS Radiopharmacies, down 6.25 percent to $US45 million.
Last year, Telix said it acquired RLS Radiopharmacies (BD: Jan 28, 2025).
Today, Telix managing-director Dr Chris Behrenbruch said the company “delivered another quarter of growth with US dose volumes increasing seven percent during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio”.
“This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution,” Dr Behrenbruch said.
“During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses,” Dr Behrenbruch said.
“We are tracking in-line with the upper end of our 2025-’2026 revenue guidance and are investing further in [research and development] to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value,” Dr Behrenbruch said.
The company said it expected total income for the year to be more than $US1 billion, with revenue tracking in-line with the upper end of 2025-’26 guidance of $US950 million to $US970 million plus $US40 million in non-refundable other income from Regeneron.
Earlier this year, Telix said it had an up-to $US2.1 billion collaboration with Tarrytown, New York’s Regeneron for cancer radio-pharmaceuticals (BD: Apr 13, 2026).
Today, the company said revenue guidance reflected “product sales in jurisdictions with marketing authorization and a full-year of revenue contribution from RLS”.
Telix said it had updated 2025-’26 research and development expenditure expectations from $US230 million to $US270 million, subject to achieving ongoing clinical data outcomes and development milestones.
The company said the additional investment would support the advancement of high-value clinical programs beyond the original forecast, including acceleration of the TLX597-TX program and label expansion for Pixclara, and progression of its Regeneron agreement.
Telix was up 21 cents or 1.4 percent to $15.31 with 2.65 million shares traded.

CONTROL BIONICS

Control Bionics says it has raised $256,000 at 7.5 cents a share in a share purchase plan, taking the total raised with the placement to $9,750,000.
Last month, Control Bionics said it had commitments to raise $9,500,000 at 7.5 cents a share, a 14.5 percent discount to five-day volume weighted average price, in a placement, with a $500,000 share purchase plan to follow (BD: Jun 25, 2026).
At the time, the company said the funds would be used for commercialization, working capital, research and development as well as business development.
Control Bionics fell 0.2 cents or 2.9 percent to 6.6 cents.

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION, TOUCH BIOTECHNOLOGY

The Australian Therapeutic Goods Administration says it has suspended sales of Touch Biotechnology's chlamydia and gonorrhoea self-tests for women until December 17, 2026.

Last year, Sydney's Touch Biotechnology said its "rapid", single-swab, self-test kit for chlamydia and gonorrhoea in women was available for sale in Australia and the test was "Australia's first [Therapeutic Goods Administration]-approved rapid self-test for chlamydia and gonorrhoea for women" (BD: Apr 15, 2025).

At the time, a spokesperson for the company told Biotech Daily that the test received TGA approval in November 2024.

Touch said the test produced a positive or negative result for both infections in 15 minutes, compared to previous laboratory or polymerase chain reaction (PCR) tests, which were an invasive process that could be costly and take one to three days for results.

According to its website, the company sold its dual chlamydia and gonorrhoea swab for $24.00 a test, which was available for purchase online as well as at pharmacies.

A media release from the Australian Therapeutic Goods Administration said a review of the diagnostics using independent laboratory testing of the analytical performance was intended to verify the performance of the device and the review suggested "false negative results in individuals who had used the device, where subsequent testing using alternative methods identified infection" but did not disclose the number of false negative cases.

The Administration said chlamydia and gonorrhoea were "nationally notifiable sexually transmissible infections" and that accurate detection of these infections was "important to support timely diagnosis, treatment and prevention of transmission".

The TGA said it "could not reproduce the analytical performance claims for limit of detection … [raising] concerns about the potential for false negative results".

The regulator said that until the issue was resolved "we consider the device is not reliable for detecting [chlamydia] and [gonorrhoea] at the claimed concentrations".

The TGA said "false negative results may lead to missed detection of infection, delays in diagnosis and treatment, and ongoing transmission".

The Administration said the sponsor was "undertaking further work to address the issues identified in the review, including demonstrating that the device can reliably detect [chlamydia] and [gonorrhoea] at the claimed concentrations".

The TGA told Biotech Daily that Touch had "co-operated with the … review of the performance of the test by providing samples for testing and responding to requests for information about the device and the manufacturer's test methods".

"We received one communication from a health service on May 13, 2026, of false negative results from this test, affecting an unspecified number of patients," the TGA said.

Biotech Daily attempted to contract Touch Biotechnology for comment, but did not receive a response by the time of publication.

The TGA said "based on the above findings, a negative result from the device does not exclude infection" and that the device should not replace assessment by a medical practitioner and was best considered as an initial screening tool.

The Administration said "individuals with ongoing risk of infection, recent exposure, or persistent symptoms should seek further evaluation, including confirmatory testing, through a healthcare professional or a sexual health clinic".

The TGA said healthcare professionals and services should be aware of the potential for false negative results associated with this device.

The regulator said "where relevant, consideration may be given to appropriate follow-up and confirmatory testing in line with local clinical practice, particularly in individuals at risk of infection".

Touch Biotechnology is a private company.

MESOBLAST

Mesoblast says founder and managing-director Prof Silviu Itescu has paid $2,733,734 to exercise 1,885,334 options, at $1.45 each, to increase his holding in the company.
Mesoblast said Dr Itescu had “not sold any of these newly acquired shares” and had increased his total shareholding to 80,844,262 shares.
According to its most recent notice, the company had 1,296,862,776 shares on issue, meaning that Prof Itescu held about 6.2 percent.
Prof Itescu said the investment reflected his “strong confidence in Mesoblast’s continued growth trajectory and its value proposition”.
Mesoblast fell 11 cents or 4.5 percent to $2.32 with five million shares traded.

TELIX PHARMACEUTICALS

Telix says it has dosed the first of about 40 patients in its phase III trial of lutetium-177 TLX250-Tx treatment for relapsed or recurrent clear cell renal cell carcinoma.
In an email not announced to the ASX, Telix said the randomized, prospective, open-label, multi-centre study of TLX250-TX was the first radio-pharmaceutical therapy to enter phase III development for clear cell renal cell carcinoma.
The company said the first patient was dosed at Perth’s Genesis Care Murdoch.
Telix chief medical officer Dr David Cade said the study was “the next stage in Telix’s global clinical development of TLX250-Tx and reflects our commitment to developing precision radio-pharmaceuticals for patients with difficult-to-treat cancers”.
“We aim to further evaluate the potential of TLX250-Tx that is designed to utilize the high prevalence of [carbonic anhydrase IX] expression in [clear cell renal cell carcinoma] to deliver targeted radiation directly to tumor sites, while limiting exposure to healthy tissue,” Dr Cade said.

OPTISCAN IMAGING

Optiscan says it has begun stage two of its clinical study of in-vivo head and neck cancer imaging at Perth’s St John of God Murdoch Hospital “ahead of schedule”.
Last year, Optiscan said it had begun a 50-patient study of its Invue and Inform microscopes for imaging head and neck cancer during surgery (BD: Dec 3, 2025).
Today, the company said the second phase of the study, allowed for live intra-operative imaging during surgery, “supporting assessment of tissue architecture and surgical margins in procedures where real-time decision-making is clinically important”.
Optiscan said the progress allowed it “to expand the types of tissues that can be imaged in the head and neck … and simultaneously result in significant time and cost savings”.
The company said imaging and pathology data generated from the study would support US Food and Drug Administration regulatory submissions, which would collate imaging data from multiple studies to show the applicability of its platform technology.
Optiscan said 10 cases had been completed in the first stage of the study.
Optiscan managing-director Prof Camile Farah said beginning stage two was “a testament to the ease of integration of both these innovative platforms into surgical and pathology workflows, as well as the strength of the collaboration between Optiscan, [St John of God Murdoch Hospital], and Australian Clinical Labs.”
“Stage one deliverables have Optiscan well on the way to demonstrating how real-time microscopic imaging can potentially support surgeons with tissue assessment and surgical decision-making during complex oncological procedures,” Prof Farah said.
Optiscan fell one cent or 6.7 percent to 14 cents.

RHYTHM BIOSCIENCES

Rhythm says it has developed a Genetype lung cancer risk prediction test using health, lifestyle and genetic data from about 500,000 people in the UK Biobank study.
Rhythm said the algorithm combined “established clinical risk factors, including age, smoking history, weight, and family history of lung cancer, with a polygenic risk score”.
The company said the polygenic risk score added-up “the small effects of many genetic variations to estimate a person’s inherited risk of developing a disease”.
Rhythm said the genetic information added “insight that clinical factors alone don’t capture, giving a fuller picture of a person’s overall risk”.
The company said when tested against current Australian screening eligibility, the Genetype test showed “greater predictive ability in identifying at-risk adults than age and smoking-history criteria alone, improving discrimination from 0.70 to 0.86”.
Rhythm said “in testing, the model identified 42 percent more lung cancer cases as eligible for screening than current Australian criteria”.
The company said it intended “to transfer this novel clinical test to production over the next quarter to support future commercialization as part of the company’s existing portfolio of Genetype risk assessment tests”.
Rhythm clinical affairs director Dr Erika Spaeth said the model was “a meaningful advance in how we identify individuals who stand to benefit most from lung cancer screening”.
“By combining genetic risk information with clinical data, we can look beyond traditional smoking thresholds and reach the people at highest risk who are currently falling through the cracks of existing programs,” Dr Spaeth said.
“Furthermore, this complements the work we are doing on blood-based biomarkers designed to ultimately be a screen for lung cancer,” Dr Spaeth said.
“The goal is to achieve the same longitudinal approach to disease for lung cancer as we have for bowel cancer, Genetype working in conjunction with Colostat,” Dr Spaeth said.
Rhythm fell 0.1 cents or 1.2 percent to 8.5 cents.

BLS PHARMACEUTICALS (FORMERLY BIOXYNE)

BLS says it has an agreement with the Ann Arbor, Michigan-based Cayman Chemical Co to introduce prospective customers for the manufacture of psilocybin and MDMA.
BLS said Cayman Chemical was “a recognized supplier of pharmaceutical-grade research chemicals and active pharmaceutical ingredients supporting pharmaceutical companies, biotechnology developers and research institutions worldwide”.
The company said the agreement established a commercial referral framework under which Cayman would introduce prospective customers seeking finished pharmaceutical dosage forms of psilocybin and 3,4-methylene-dioxy-methamphetamine (MDMA) to BLS, and it would manufacture and supply patient-ready dosage products in accordance with applicable regulatory requirements.
BLS did not disclose the commercial terms of the agreement.
BLS managing-director Sam Watson said the company was “delighted to further develop our relationship with Cayman Chemical”.
“This agreement expands our international commercial reach and will result in Cayman Chemicals referring enquiries from the US customers for psychedelic finished medication to BLS for fulfilment,” Mr Watson said. “Importantly, we have held the manufacturing licences and regulatory approvals this sector needs for some time and are already a significant supplier of pharmaceutical-grade MDMA and psilocybin products used within Australia's regulated psychedelic medicines framework.”
BLS fell five cents or 5.6 percent to a post-consolidation 84 cents.

PYC THERAPEUTICS

PYC says cynomolgus monkey studies show “an increase in target gene expression in the retina four months after a single dose of PYC-001” for autosomal dominant optic atrophy.
PYC said a single dose of PYC-001 at 15 micrograms (µg) per eye, the equivalent of the 30µg human dose being studied in its phase Ia/Ib trial, showed “a sustained increase in OPA1 protein expression in the retina four months after a single administration”.
The company said autosomal dominant optic atrophy was “caused by an about 50 percent reduction in OPA1 expression in the retinal ganglion cells”.
Last year, PYC said it dosed the first of 15 patients in the multiple ascending dose, phase Ib study of PYC-001 for ADOA following a nine-patient, single ascending dose study showing “no safety concerns” related to PYC-001 (BD: Oct 9, 21, 2025).
Today, the company said autosomal dominant optic atrophy patients in the trials of PYC-003 showed “sustained improvement in both visual acuity and retinal stress following repeat doses of the drug candidate”, as measured by immuno-fluorescence.
PYC said the combination of data sets supported “both an extension of the dosing interval in PYC’s … trials in [autosomal dominant optic atrophy] as well as exploration of the utility of the investigational drug candidate in other blinding eye diseases”.
The company said it was “evaluating the utility of PYC-001 in pre-clinical models of glaucoma with a view to initiating a phase II study in glaucoma patients”.
PYC was up one cent or 0.6 percent to $1.625 with 1.2 million shares traded.

IDT AUSTRALIA

IDT says unaudited revenue for the year to June 30, 2026 is expected to be up 2.5 percent to $20.3 million, with loss tax down 84.9 percent to $950,000.
Last year, IDT said revenue for the year to June 30, 2025 from manufacturing services for pharmaceuticals including specialty oral products, medical marijuana and psychedelics as well as active pharmaceutical ingredients rose 40.6 percent to $19,861,000, with net loss of $8,063,000 (BD: Aug 21, 2025).
Today, the company said it expected negative earnings before interest, taxation, depreciation and amortization (Ebitda) to be down 84.9 percent to negative $950,000.
IDT said the guidance included demand for its facilities and drug manufacturing services, and “cost savings running ahead of target”.
IDT was up 0.9 cents or 28.1 percent to 4.1 cents.

CLINUVEL PHARMACEUTICALS

Clinuvel fell 25 US cents (36 Australian cents) or 3.27 percent to $US7.40 ($A10.56) per American depository shares (ADS) following its uplift to a Level II Nasdaq listing.
Last year, Clinuvel said it would upgrade its level I American depository receipts (ADRs) to a level II listing on the Nasdaq (BD: Aug 22, 2025).
The company said its American depositary shares began trading on the Nasdaq Stock Market on July 20 (US EST) under the symbol CUVL, completing “the uplift”.
Clinuvel said holders of CLVLY ADRs should contact their brokers for any queries.
Clinuvel fell 19 cents or 1.9 percent to $10.05 with 182,309 shares traded.